抗PD-1/PD-Ls抗体在肿瘤治疗中的应用研究进展
摘要
<正>癌症是人类健康的最大挑战之一,因癌症失去生命的人数与日俱增。为了与癌症进行抗争,人类走上了漫漫求索之路,研究~([1])发现免疫疗法治疗肿瘤有显著成效。免疫防御是免疫系统的一大功能,能使机体免受癌症等各种疾病的侵袭。癌细胞能通过免疫逃避在体内大量增殖,例如癌细胞表面主要组织相容性复合体Ⅰ(MHCⅠ)类分子作用受抑制,合成免疫抑制因子,抑制免疫防御功能在体内增殖分化。因此,恢复免疫防御作用是抗癌研究的一个重要手段。与传统治疗手段相比,肿瘤免疫疗
引文
[1] SMYTH MJ,GODFREY DI,TRAPANI JA.A fresh look at tumor immunosurveillance and immunotherapy[J].Nat Immunol,2001,2(4):293.
[2] ATKINS MB,SZNO ML.Cancer immunotherapy:past progress and future directions[J].Semin Oncol,2015,42(4):518.
[3] PAGE DB,POSTOW MA,CALLAHAN MK,et al.Immunemodulation in cancer with antibodies[J].Annu Rev Med,2013,65(1):185.
[4] KERSHAW MH,WESTWOOD JA,SLANEY CY,et al.Clinical application of genetically modified T cells in cancer therapy[J].Clin Transl Immunol,2014,3:16.
[5] ROSENBERG SA.Raising the bar:the curative potential of human cancerimmunotherapy[J].Sci Transl Med,2012,127(4):127ps8.
[6] ROBERT C,SCHACHTER J,LONG GV,et al.Pembrolizumab versus ipilimumab in advanced melanoma[J].N Engl J Med,2015,372(26):2521.
[7] ISHIDA Y,AGATA Y,SHIBAHARA K,et al.Induced expression of PD-1,a novel member of the immunolobin gene superfamily,upon programmed cell-death[J].Embv J,1992,11(11):3887.
[8] DONG H,ZHU G,TAMADA K,et al.B7-H1,a third member of the B7 family,co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med,1999,5(12):1365.
[9] FREEMAN GJ,LONG AJ IWAI Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med,2000,192(7):1027.
[10] SUN H,SUN C,XIAO W.Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokinestimulations[J].Cytokine,2014,65(1):33.
[11] IRAOLAGOITIA XL,SPALLANZANI RG,TORRES NI,et al.NK cells restrain spontaneous antitumor CD8+ Tcell priming through PD-1/PD-L1 interactions with dendritic cells[J].J Immunol,2016,197(3):953.
[12] LATCHMAN Y WOOD CR,CHERNOVA T,et al.PD-L2 is a second ligand for PD-1and inhibits Tcell activation[J].Nat Immunol,2001,2(3):261.
[13] STEMPIN CC,MOTRAN CC,AOKI MP,et al.PD-L2 negatively regulates Th1-mediated immunopathology during Fasciola hepaticainfection[J].Oncotarget,2016,7(47):77721.
[14] CHEMNITZ JM,PARRY RV,NICHOLS KE,et al.SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human Tcell stimulation,but only receptor ligation prevents Tcell activation[J].J Immunol,2004,173(2):945.
[15] LASTWIKA KJ,WILSON W,LI QK,et al,Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer Res[J].Oncogene,2016,72(2):227.
[16] KOH YW,JEON YK,YOON DH,et al.Programmed death 1 expression the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma[J].Tumour Biol,2016,37(6):7507.
[17] TOPALIAN SL,DRAKE CG,PARDOLL DM.Immune checkpoint blockade:a common denominator approach to cancer therapy[J].Cancer Cell,2015,27(4):450.
[18] PARSA AT,WALDRON JS,PANNER A,et al.Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma[J].Nat Med,2007,13(1):84.
[19] 景楚瑜.抗PD-1/PD-L1治疗在肿瘤治疗中的研究进展[J].复旦学报,2016,43(6):1672.
[20] ZIPPELIUS A,SCHREINER J,HERZIG P,et al.Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment[J].Cancer Immunol Res,2015,3(3):236.
[21] MURPHY K,TRAVERS P,WALPORT M.Janeway′s immunobiology[M].8th.Beijing:Garland Science,2011:685.
[22] 张力.非小细胞肺癌的免疫治疗新进展[J].医学与哲学,2015,36(4):13.
[23] 赖胜蓝,王江涛.非小细胞肺癌抗PD-1/PD-L1治疗研究进展[J].中国继续医学教育,2017,9(1):145.
[24] DONG H,STROME SE,SALOMAO DR,et al.Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion[J].Nat Med,2002,8(8):793.
[25] 潘佳佳,贾晓青,黄岗,等.PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用[J].中国药科大学学报,2016,47(1):9.
[26] 徐泱,喻敏成.抗PD-1/PD-L1抗体在肿瘤治疗中的研究[J].外科与理论实践,2018,23(3):227.
[27] TROJAN J,SARRAZIN C.Complete response of hepatocellular carcinoma in a patient with end-stage liver disease treated with nivolumab:whishful thinking or possible?[J].Am J Gastroenterol,2016,111(8):1208.
[28] 高蓓蓓,李代强.PD-1/PD-L1在非小细胞瘤肺癌中的研究进展及展望[J].临床与病理杂志,2015,35(6):1189.
[29] HUI R,GARON EB,GOLDMAN JW,et al.Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer:a phase 1 trial[J].Ann Oncol,2017,28(4):874.
[30] GOLDBERG SB,GETTINGER SN,MAHAJAN A,et al.Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:early analysis of a non-randomised,open-label,phase 2 trial[J].Lancet Oncol,2016,17(7):976.
[31] ATKINS MB,KUDCHADKAR RR,SZNOL M,et al.Phase 2,multi center,safety and efficacy study of pidilizumab in patients with metastatic melanoma[C].ASCO Annual Meeting Proceedings,2014,32(15):9001.
[32] WESTIN JR,CHU F,ZHANG M,et al.Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma:a single group,open label,phase 2 trial[J].Lancet Oncol,2014,15(1):69.
[33] KAYLA FAITH MOORE,PHARM D.Use of Atezolizumabfor bladder cancer and NSCLC[J].Med Lett Drugs Ther,2017,1515(59):40.
[34] KAUFMAN HL,RUSSELL J,HAMID O,et al.Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma:a multicentre,single-group,open-label,phase 2 trial[J].Lancet Oncol,2016,17(10):1374.
[35] POWLES T,EDER JP,FINE GD,et al.MPDL3280A ( anti-PD-L1)treatment leads to clinical activity in metastatic bladder cancer[J].Nature,2014,7528(515):558.
[36] EMENS LA,BRAITEH FS,CASSIER P,et al.Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer[J].Cancer Res,2015,75(15 Suppl):2859.
[37] SEGAL NH,ANTONIA SJ,BRAHMER JR,et al.Preliminary data from amulti-arm expansion study of MEDI4736,an anti-PD-L1 antibody[J].J Clin Oncol,2014,32(15 Suppl):134136.
[38] BRAHMER JR,TYKODI SS,CHOW LQ,et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J].N Engl J Med,2012,366(26):2455.
[39] DISIS ML,PATEL MR,PANT S,et al.Avelumab(MSB0010718C),an anti-PD-L1 antibodyin patients with previously treated,recurrent or refractory ovarian cancer:a phase Ib,open-labelexpansion trial[C].ASCO Annual Meeting Proceedings,2015,33(15 Suppl):5509.
[40] POSTOW MA,CALLAHAN MK,WOLCHOK JD.Immune checkpoint blockade in cancer therapy[J].J Clin Oncol,2015,33(17):1974.
[41] FRIEDMAN CF,PROVERBS-SINGH TA,POSTOW MA.Treatment of tne immune-related adverse effects of immune checkpoint inhibitors:a review[J].JAMA Oncol,2016,2(10):1346.
[42] CALABRESE L,MARIETTE X.The evolving role of the rheumatologist in the management of immune-related adverse events(irAEs) caused by cancer immunotherapy[J].Ann Rheum Dis 2018,77(2):162.
[43] 喻敏成,胡博,付佩尧,等.抗PD-1/PD-L1抗体临床治疗不良反应研究进展[J].中国临床医学,2018,25(4):625.
[2] ATKINS MB,SZNO ML.Cancer immunotherapy:past progress and future directions[J].Semin Oncol,2015,42(4):518.
[3] PAGE DB,POSTOW MA,CALLAHAN MK,et al.Immunemodulation in cancer with antibodies[J].Annu Rev Med,2013,65(1):185.
[4] KERSHAW MH,WESTWOOD JA,SLANEY CY,et al.Clinical application of genetically modified T cells in cancer therapy[J].Clin Transl Immunol,2014,3:16.
[5] ROSENBERG SA.Raising the bar:the curative potential of human cancerimmunotherapy[J].Sci Transl Med,2012,127(4):127ps8.
[6] ROBERT C,SCHACHTER J,LONG GV,et al.Pembrolizumab versus ipilimumab in advanced melanoma[J].N Engl J Med,2015,372(26):2521.
[7] ISHIDA Y,AGATA Y,SHIBAHARA K,et al.Induced expression of PD-1,a novel member of the immunolobin gene superfamily,upon programmed cell-death[J].Embv J,1992,11(11):3887.
[8] DONG H,ZHU G,TAMADA K,et al.B7-H1,a third member of the B7 family,co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med,1999,5(12):1365.
[9] FREEMAN GJ,LONG AJ IWAI Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med,2000,192(7):1027.
[10] SUN H,SUN C,XIAO W.Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokinestimulations[J].Cytokine,2014,65(1):33.
[11] IRAOLAGOITIA XL,SPALLANZANI RG,TORRES NI,et al.NK cells restrain spontaneous antitumor CD8+ Tcell priming through PD-1/PD-L1 interactions with dendritic cells[J].J Immunol,2016,197(3):953.
[12] LATCHMAN Y WOOD CR,CHERNOVA T,et al.PD-L2 is a second ligand for PD-1and inhibits Tcell activation[J].Nat Immunol,2001,2(3):261.
[13] STEMPIN CC,MOTRAN CC,AOKI MP,et al.PD-L2 negatively regulates Th1-mediated immunopathology during Fasciola hepaticainfection[J].Oncotarget,2016,7(47):77721.
[14] CHEMNITZ JM,PARRY RV,NICHOLS KE,et al.SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human Tcell stimulation,but only receptor ligation prevents Tcell activation[J].J Immunol,2004,173(2):945.
[15] LASTWIKA KJ,WILSON W,LI QK,et al,Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer Res[J].Oncogene,2016,72(2):227.
[16] KOH YW,JEON YK,YOON DH,et al.Programmed death 1 expression the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma[J].Tumour Biol,2016,37(6):7507.
[17] TOPALIAN SL,DRAKE CG,PARDOLL DM.Immune checkpoint blockade:a common denominator approach to cancer therapy[J].Cancer Cell,2015,27(4):450.
[18] PARSA AT,WALDRON JS,PANNER A,et al.Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma[J].Nat Med,2007,13(1):84.
[19] 景楚瑜.抗PD-1/PD-L1治疗在肿瘤治疗中的研究进展[J].复旦学报,2016,43(6):1672.
[20] ZIPPELIUS A,SCHREINER J,HERZIG P,et al.Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment[J].Cancer Immunol Res,2015,3(3):236.
[21] MURPHY K,TRAVERS P,WALPORT M.Janeway′s immunobiology[M].8th.Beijing:Garland Science,2011:685.
[22] 张力.非小细胞肺癌的免疫治疗新进展[J].医学与哲学,2015,36(4):13.
[23] 赖胜蓝,王江涛.非小细胞肺癌抗PD-1/PD-L1治疗研究进展[J].中国继续医学教育,2017,9(1):145.
[24] DONG H,STROME SE,SALOMAO DR,et al.Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion[J].Nat Med,2002,8(8):793.
[25] 潘佳佳,贾晓青,黄岗,等.PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用[J].中国药科大学学报,2016,47(1):9.
[26] 徐泱,喻敏成.抗PD-1/PD-L1抗体在肿瘤治疗中的研究[J].外科与理论实践,2018,23(3):227.
[27] TROJAN J,SARRAZIN C.Complete response of hepatocellular carcinoma in a patient with end-stage liver disease treated with nivolumab:whishful thinking or possible?[J].Am J Gastroenterol,2016,111(8):1208.
[28] 高蓓蓓,李代强.PD-1/PD-L1在非小细胞瘤肺癌中的研究进展及展望[J].临床与病理杂志,2015,35(6):1189.
[29] HUI R,GARON EB,GOLDMAN JW,et al.Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer:a phase 1 trial[J].Ann Oncol,2017,28(4):874.
[30] GOLDBERG SB,GETTINGER SN,MAHAJAN A,et al.Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:early analysis of a non-randomised,open-label,phase 2 trial[J].Lancet Oncol,2016,17(7):976.
[31] ATKINS MB,KUDCHADKAR RR,SZNOL M,et al.Phase 2,multi center,safety and efficacy study of pidilizumab in patients with metastatic melanoma[C].ASCO Annual Meeting Proceedings,2014,32(15):9001.
[32] WESTIN JR,CHU F,ZHANG M,et al.Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma:a single group,open label,phase 2 trial[J].Lancet Oncol,2014,15(1):69.
[33] KAYLA FAITH MOORE,PHARM D.Use of Atezolizumabfor bladder cancer and NSCLC[J].Med Lett Drugs Ther,2017,1515(59):40.
[34] KAUFMAN HL,RUSSELL J,HAMID O,et al.Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma:a multicentre,single-group,open-label,phase 2 trial[J].Lancet Oncol,2016,17(10):1374.
[35] POWLES T,EDER JP,FINE GD,et al.MPDL3280A ( anti-PD-L1)treatment leads to clinical activity in metastatic bladder cancer[J].Nature,2014,7528(515):558.
[36] EMENS LA,BRAITEH FS,CASSIER P,et al.Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer[J].Cancer Res,2015,75(15 Suppl):2859.
[37] SEGAL NH,ANTONIA SJ,BRAHMER JR,et al.Preliminary data from amulti-arm expansion study of MEDI4736,an anti-PD-L1 antibody[J].J Clin Oncol,2014,32(15 Suppl):134136.
[38] BRAHMER JR,TYKODI SS,CHOW LQ,et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J].N Engl J Med,2012,366(26):2455.
[39] DISIS ML,PATEL MR,PANT S,et al.Avelumab(MSB0010718C),an anti-PD-L1 antibodyin patients with previously treated,recurrent or refractory ovarian cancer:a phase Ib,open-labelexpansion trial[C].ASCO Annual Meeting Proceedings,2015,33(15 Suppl):5509.
[40] POSTOW MA,CALLAHAN MK,WOLCHOK JD.Immune checkpoint blockade in cancer therapy[J].J Clin Oncol,2015,33(17):1974.
[41] FRIEDMAN CF,PROVERBS-SINGH TA,POSTOW MA.Treatment of tne immune-related adverse effects of immune checkpoint inhibitors:a review[J].JAMA Oncol,2016,2(10):1346.
[42] CALABRESE L,MARIETTE X.The evolving role of the rheumatologist in the management of immune-related adverse events(irAEs) caused by cancer immunotherapy[J].Ann Rheum Dis 2018,77(2):162.
[43] 喻敏成,胡博,付佩尧,等.抗PD-1/PD-L1抗体临床治疗不良反应研究进展[J].中国临床医学,2018,25(4):625.